Collectively, these results provide a strong pre-clinical rationale for TTI-101 as a therapeutic strategy for SMARCB1-deficient BLCA with concomitant activation of pSTAT3 (Fig. 6E). This evidence concerns the gene SMARCB1 and bladder transitional cell carcinoma.